SAN FRANCISCO – The number of completed mergers and acquisitions in the biopharma industry mushroomed in 2015, generating a total deal value of more than $300 billion, establishing a new record for the industry, according to EY's Firepower Index and Growth Gap Report 2016. Read More
SAN FRANCISCO – The capital markets were already ugly heading into the 34th J.P. Morgan Healthcare conference (JPM) and they got even worse by the day as biopharma companies strutted their stuff for four intense days of presentations. Although the overall message that resulted from the event is that the industry is alive and well with strong fundamentals, it didn't translate into a positive performance on the markets until the final day of the meeting. Read More
